Relapsed/Refractory

Oncology·MeSH: Recurrence
107 drugs in development·49 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(24)
DrugCompany
alxn2075ALEXION PHARMACEUTICALS, INC. (ALXN)
BlinatumomabENANTA PHARMACEUTICALS INC (ENTA)
bortezomibAbbVie Inc. (ABBV)
carfilzomibSanofi (SNY)
cemiplimab+fianlimab fixed dose combinationREGENERON PHARMACEUTICALS, INC. (REGN)
epcoritamabGenmab A/S (GMAB)
fdc fianlimab+cemiplimabREGENERON PHARMACEUTICALS, INC. (REGN)
hmpl-760HUTCHMED (China) Ltd (HMDCF)
HMPL-760ENANTA PHARMACEUTICALS INC (ENTA)
InotuzumabENANTA PHARMACEUTICALS INC (ENTA)
kte-c19Kite Pharma, Inc. (KITE)
ObinutuzumabBeOne Medicines Ltd. (ONC)
olverembatinibCHINA PHARMA HOLDINGS, INC. (CPHI)
PomalidomideBeOne Medicines Ltd. (ONC)
r-gemoxHUTCHMED (China) Ltd (HMDCF)
R-GemOxENANTA PHARMACEUTICALS INC (ENTA)
regn15505+cemiplimabREGENERON PHARMACEUTICALS, INC. (REGN)
sonrotoclaxBeOne Medicines Ltd. (ONC)
SonrotoclaxENANTA PHARMACEUTICALS INC (ENTA)
tazemetostatEpizyme, Inc. (EPZM)
tirabrutinibEton Pharmaceuticals, Inc. (ETON)
tirabrutinibDeciphera Pharmaceuticals, Inc. (DCPH)
tirabrutinibWest Pharmaceutical Services Inc. (WST)
uproleselanApollomics Inc. (APLM)
Phase 2(23)
DrugCompany
ABT-199AbbVie Inc. (ABBV)
ALLO-501Allogene Therapeutics, Inc. (ALLO)
ALLO-501AAllogene Therapeutics, Inc. (ALLO)
ALLO-647Allogene Therapeutics, Inc. (ALLO)
allo-715Allogene Therapeutics, Inc. (ALLO)
BendamustineFATE THERAPEUTICS INC (FATE)
CyclophophamideAllogene Therapeutics, Inc. (ALLO)
diphenhydramineSanofi (SNY)
FludarabineAllogene Therapeutics, Inc. (ALLO)
FludarabineFATE THERAPEUTICS INC (FATE)
impt-314Lyell Immunopharma, Inc. (LYEL)
Inotuzumab ozogamicinENANTA PHARMACEUTICALS INC (ENTA)
isatuximabSanofi (SNY)
IsatuximabSanofi (SNY)
montelukastSanofi (SNY)
MontelukastSanofi (SNY)
PirtobrutinibENANTA PHARMACEUTICALS INC (ENTA)
PirtobrutinibFilana Therapeutics Inc. (FLNA)
r-gemoxHUTCHMED (China) Limited (HCM)
rtx-224Rubius Therapeutics, Inc. (RUBY)
rtx-240Rubius Therapeutics, Inc. (RUBY)
sl-701STEMLINE THERAPEUTICS INC (STML)
ZanubrutinibENANTA PHARMACEUTICALS INC (ENTA)
Phase 1(34)
DrugCompany
[14C]ABT-199AbbVie Inc. (ABBV)
apg-3288ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
ARV-393ARVINAS, INC. (ARVN)
ATA3219Atara Biotherapeutics, Inc. (ATRA)
AUTO6NGAutolus Therapeutics plc (AUTL)
B7-H3-CAR T CellsMerus N.V. (MRUS)
cemiplimabREGENERON PHARMACEUTICALS, INC. (REGN)
DVX201 (Unmodified Natural Killer Cells)Coeptis Therapeutics Holdings Inc. (COEP)
E7777 (LYMPHIR) prior to CAR-TCITIUS ONCOLOGY, INC. (CTOR)
Efbalropendekin alfa (XmAb306 / RG6323)Xencor Inc (XNCR)
EpcoritamabFilana Therapeutics Inc. (FLNA)
EpcoritamabELI LILLY & Co (LLY)
EpcoritamabENANTA PHARMACEUTICALS INC (ENTA)
FludarabineNEKTAR THERAPEUTICS (NKTR)
FT522FATE THERAPEUTICS INC (FATE)
gtb-3650GT Biopharma, Inc. (GTBP)
Hyper-CVADENANTA PHARMACEUTICALS INC (ENTA)
Hyper-CVADMerus N.V. (MRUS)
KT-333Kymera Therapeutics, Inc. (KYMR)
lisaftoclaxASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
LUCAR-G79 T cellsLegend Biotech Corp (LEGN)
LYMPHIR (investigator-initiated: pre-CAR-T)CITIUS ONCOLOGY, INC. (CTOR)
Mini-hyper-CVDENANTA PHARMACEUTICALS INC (ENTA)
Mini-hyper-CVDMerus N.V. (MRUS)
mk-4002Merck & Co., Inc. (MRK)
mt-6402Molecular Templates, Inc. (MTEM)
nirogacestatAllogene Therapeutics, Inc. (ALLO)
nxc-201Immix Biopharma, Inc. (IMMX)
obinutuzumabBeOne Medicines Ltd. (ONC)
olverembatinibASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
RevumenibSyndax Pharmaceuticals Inc (SNDX)
sar445514Sanofi (SNYNF)
sar445514Sanofi (SNY)
sti-1492Sorrento Therapeutics, Inc. (SRNE)

Compare drugs

alxn2075 vs Blinatumomabalxn2075 vs bortezomibalxn2075 vs carfilzomib

Frequently asked questions

How many drugs are in development for Relapsed/Refractory?

BioSniper tracks 107 drugs in development for Relapsed/Refractory across 49 companies.

How many clinical trials target Relapsed/Refractory?

There are 1 clinical trial targeting Relapsed/Refractory tracked by BioSniper.

Deep-dive into Relapsed/Refractory

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis